Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy
1997

Intraperitoneal Mitomycin C for Abdominal Cancer

Sample size: 11 publication Evidence: low

Author Information

Author(s): SS Ubhil, P McCulloch, PS Veitch

Primary Institution: Leicester Royal Infirmary NHS Trust

Hypothesis

Is intraperitoneal mitomycin C safe and effective for treating intra-abdominal malignancies?

Conclusion

The study found that intraperitoneal mitomycin C is not safe in the presence of anastomosis or suture lines, leading to severe complications.

Supporting Evidence

  • Four out of seven patients who underwent gastric resection developed fatal complications.
  • Complications included multiple organ failure and coeliac axis rupture, which are unusual for gastrectomy.
  • The treatment was associated with a high incidence of severe complications compared to previous studies.

Takeaway

Doctors tried a new treatment for stomach cancer using a special medicine, but it made some patients very sick and even caused deaths.

Methodology

Patients received various doses of mitomycin C adsorbed onto activated carbon particles during surgery.

Potential Biases

The older age of British patients compared to Japanese patients may have influenced the results.

Limitations

The study had a small sample size and was not a formal phase I study with dose escalation.

Participant Demographics

Eleven patients, mostly older males with gastric adenocarcinoma and pseudomyxoma.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication